Latest Ratios: P/E Ratio 12.7x · EV/EBITDA 9.6x · ROE 66.0%. (2010–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $32.0B | $55.8B | $74.1B | $91.2B | $68.9B | $116.3B | $79.2B | $63.8B | $41.6B | $35.5B | $26.7B |
| Enterprise Value | $39.2B | $63.0B | $78.9B | $96.0B | $73.4B | $119.6B | $83.0B | $68.4B | $46.5B | $38.9B | $30.4B |
| P/E Ratio → | 12.67 | 20.90 | 29.79 | 38.93 | 32.64 | 57.15 | 48.39 | 42.56 | 29.19 | 41.17 | 32.44 |
| P/S Ratio | 3.38 | 5.90 | 8.01 | 10.68 | 8.53 | 14.96 | 11.87 | 10.19 | 7.15 | 6.69 | 5.46 |
| P/B Ratio | 10.17 | 16.76 | 15.54 | 18.28 | 15.66 | 25.60 | 20.99 | 23.55 | 19.06 | 19.89 | 17.79 |
| P/FCF | 14.01 | 24.46 | 32.25 | 56.29 | 51.99 | 67.01 | 47.34 | 47.76 | 28.68 | 31.66 | 53.66 |
| P/OCF | 11.01 | 19.23 | 25.10 | 38.78 | 36.05 | 52.57 | 37.25 | 35.52 | 23.27 | 26.39 | 37.41 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.66 | 8.52 | 11.23 | 9.09 | 15.38 | 12.43 | 10.93 | 7.98 | 7.33 | 6.22 |
| EV / EBITDA | 9.59 | 15.43 | 20.28 | 26.95 | 21.65 | 36.79 | 30.61 | 28.17 | 21.24 | 19.76 | 18.50 |
| EV / EBIT | 10.89 | 17.59 | 23.37 | 30.04 | 25.39 | 43.90 | 36.95 | 33.50 | 24.45 | 22.89 | 21.82 |
| EV / FCF | — | 27.61 | 34.32 | 59.19 | 55.39 | 68.89 | 49.59 | 51.27 | 32.03 | 34.68 | 61.19 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.5% | 70.5% | 69.1% | 68.3% | 67.8% | 68.3% | 66.8% | 65.7% | 65.2% | 64.9% | 64.3% |
| Operating Margin | 38.0% | 38.0% | 36.6% | 35.9% | 36.2% | 36.0% | 34.0% | 32.2% | 32.3% | 32.5% | 28.7% |
| Net Profit Margin | 28.2% | 28.2% | 26.9% | 27.4% | 26.2% | 26.2% | 24.5% | 24.0% | 24.5% | 16.3% | 16.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 66.0% | 66.0% | 50.9% | 49.9% | 47.3% | 49.0% | 50.5% | 61.3% | 71.9% | 52.6% | 63.4% |
| ROA | 18.0% | 18.0% | 17.4% | 16.0% | 14.7% | 14.8% | 13.0% | 13.4% | 14.7% | 10.6% | 10.6% |
| ROIC | 26.9% | 26.9% | 26.5% | 24.7% | 26.3% | 27.4% | 22.8% | 21.0% | 23.1% | 24.9% | 21.0% |
| ROCE | 29.9% | 29.9% | 29.2% | 25.4% | 24.5% | 23.8% | 21.4% | 20.9% | 22.1% | 24.6% | 22.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.85 | 2.85 | 1.41 | 1.35 | 1.84 | 1.48 | 1.95 | 2.44 | 2.95 | 2.77 | 2.98 |
| Debt / EBITDA | 2.32 | 2.32 | 1.73 | 1.90 | 2.38 | 2.07 | 2.72 | 2.72 | 2.95 | 2.52 | 2.72 |
| Net Debt / Equity | — | 2.16 | 1.00 | 0.94 | 1.02 | 0.72 | 1.00 | 1.73 | 2.22 | 1.90 | 2.50 |
| Net Debt / EBITDA | 1.76 | 1.76 | 1.22 | 1.32 | 1.33 | 1.00 | 1.39 | 1.93 | 2.22 | 1.72 | 2.28 |
| Debt / FCF | — | 3.15 | 2.07 | 2.91 | 3.40 | 1.88 | 2.25 | 3.50 | 3.34 | 3.02 | 7.53 |
| Interest Coverage | 14.74 | 14.74 | 13.95 | 12.38 | 12.21 | 11.54 | 9.02 | 8.44 | 8.97 | 9.71 | 8.40 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.03 | 3.03 | 1.75 | 3.36 | 2.37 | 3.86 | 3.05 | 2.63 | 3.60 | 3.85 | 3.03 |
| Quick Ratio | 1.94 | 1.94 | 1.08 | 2.00 | 1.63 | 2.79 | 2.30 | 1.85 | 2.46 | 2.55 | 1.69 |
| Cash Ratio | 1.03 | 1.03 | 0.58 | 1.08 | 1.13 | 1.94 | 1.66 | 1.07 | 1.39 | 1.43 | 0.65 |
| Asset Turnover | — | 0.61 | 0.65 | 0.60 | 0.54 | 0.56 | 0.49 | 0.54 | 0.54 | 0.62 | 0.64 |
| Inventory Turnover | 1.15 | 1.15 | 1.24 | 1.06 | 1.11 | 1.28 | 1.36 | 1.52 | 1.46 | 1.31 | 1.16 |
| Days Sales Outstanding | — | 61.30 | 51.90 | 55.71 | 54.89 | 53.18 | 55.39 | 63.32 | 64.92 | 68.64 | 68.18 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 2.6% | 1.6% | 1.1% | 0.8% | 0.9% | 0.4% | 0.5% | 0.5% | 0.6% | 0.6% | 0.7% |
| Payout Ratio | 33.3% | 33.3% | 31.6% | 29.5% | 28.9% | 23.3% | 23.2% | 20.9% | 17.0% | 23.8% | 22.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 7.9% | 4.8% | 3.4% | 2.6% | 3.1% | 1.7% | 2.1% | 2.3% | 3.4% | 2.4% | 3.1% |
| FCF Yield | 7.1% | 4.1% | 3.1% | 1.8% | 1.9% | 1.5% | 2.1% | 2.1% | 3.5% | 3.2% | 1.9% |
| Buyback Yield | 10.1% | 5.8% | 2.5% | 1.2% | 2.3% | 0.6% | 0.3% | 1.0% | 1.7% | 1.4% | 1.1% |
| Total Shareholder Yield | 12.7% | 7.4% | 3.6% | 2.0% | 3.2% | 1.0% | 0.8% | 1.5% | 2.3% | 2.0% | 1.8% |
| Shares Outstanding | — | $444M | $455M | $462M | $470M | $477M | $479M | $482M | $487M | $493M | $498M |
Rising leverage and debt
According to current market data, Zoetis trades at a trailing P/E of 12.63, which appears to discount the recent deceleration in top-line growth and suggests that investors are increasingly skeptical of the company's ability to maintain its historical premium relative to broader pharmaceutical and animal health peers.
The current PEG ratio of 1.06 indicates that the market is pricing in a moderate growth trajectory, yet the compression in forward multiples suggests a potential re-rating if innovation-led revenue fails to accelerate. Investors should monitor whether the current valuation adequately accounts for the transition from pandemic-era volume surges to a more normalized, price-driven growth environment.
Based on quarterly financial statements, Zoetis's ROIC has trended downward to 5.9% in 2026Q1 from a 2025Q2 peak of 7.4%, indicating that the company's ability to compound returns on invested capital is currently being challenged by rising debt levels and a more capital-intensive product mix.
The decline in ROIC suggests that recent capital allocation decisions, particularly aggressive share repurchases, may be eroding the efficiency of the underlying asset base. This trend warrants further investigation into whether the company's R&D investments in biologics are generating sufficient incremental returns to offset the dilution of the equity base.
As reported in recent filings, the cash conversion cycle has remained elevated at 341 days in 2026Q1, primarily driven by a bloated inventory position that suggests potential inefficiencies in managing supply chain logistics for a global, multi-channel distribution network compared to historical performance.
The persistent DIO (Days Inventory Outstanding) of 350 days indicates that the company is carrying significant inventory, which may be a strategic buffer or a sign of slowing end-user demand. This working capital intensity limits free cash flow generation and suggests that operational leverage is currently being hampered by inventory management challenges.
According to the latest balance sheet data, the debt-to-equity ratio has surged to 2.86 in 2026Q1, a significant departure from historical norms that indicates a more aggressive reliance on debt to fund capital returns and operations in a higher interest rate environment.
While the interest coverage ratio of 13.26 remains adequate, the rapid increase in leverage relative to equity suggests a narrowing margin of safety for the balance sheet. Investors should monitor whether this debt trajectory necessitates a shift in capital allocation priorities to preserve financial flexibility.
The P/E ratio is frequently misapplied to Zoetis because it fails to account for the lumpy nature of R&D-heavy biological manufacturing and the significant impact of non-cash amortization, which often obscures the underlying cash-generating capacity of the company's proprietary monoclonal antibody portfolio.
Analysts should instead focus on EV/EBITDA or FCF-based valuation metrics to better capture the true operational performance of the business. Relying solely on P/E ignores the structural durability of the company's biologics moat, which may provide a longer, more stable earnings tail than traditional small-molecule pharmaceutical models suggest.
Includes 30+ ratios · 16 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ZTS stock.
Zoetis Inc.'s current P/E ratio is 12.7x. The historical average is 39.5x.
Zoetis Inc.'s current EV/EBITDA is 9.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 23.8x.
Zoetis Inc.'s return on equity (ROE) is 66.0%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 42.7%.
Based on historical data, Zoetis Inc. is trading at a P/E of 12.7x. Compare with industry peers and growth rates for a complete picture.
Zoetis Inc.'s current dividend yield is 2.63% with a payout ratio of 33.3%.
Zoetis Inc. has 70.5% gross margin and 38.0% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Zoetis Inc.'s Debt/EBITDA ratio is 2.3x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.